Sign up to save your podcasts
Or
Share Multiple Myeloma ASH 2024 Highlights with Dr. Robert Orlowski
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Multiple Myeloma ASH 2024 Highlights with Dr. Robert Orlowski
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Robert Orlowski from MD Anderson Cancer Center to discuss groundbreaking studies presented at ASH 2024 focused on multiple myeloma.
We dived into four key studies:
1. AQUILA: Explore the impact of early intervention using daratumumab for smoldering myeloma, which showed improved progression-free survival (PFS) and overall survival (OS).
2. Dara Based Quad Therapy: We discuss a meta-analysis reaffirming the use of quadruplet therapy with anti-CD38 for newly diagnosed multiple myeloma as the standard of care.
3. CARTITUDE-4: study highlights the benefits of CAR-T therapy in earlier lines of treatment for patients with lenalidomide-refractory disease.
4. Role of IVIG with BCMA Bispecific Antibodies: Discover how IVIG can reduce infection rates and improve overall survival when used alongside BCMA-targeted therapies.
Tune in for an insightful discussion that will enhance your understanding of the latest advancements in multiple myeloma treatment. Don't forget to check out our other episodes on CLL, myeloma, and lymphoma from ASH 2024!
Subscribe to the Oncology Brothers for more updates and expert insights in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
View all episodes
By Oncology Brothers
4.8
4040 ratings
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Robert Orlowski from MD Anderson Cancer Center to discuss groundbreaking studies presented at ASH 2024 focused on multiple myeloma.
We dived into four key studies:
1. AQUILA: Explore the impact of early intervention using daratumumab for smoldering myeloma, which showed improved progression-free survival (PFS) and overall survival (OS).
2. Dara Based Quad Therapy: We discuss a meta-analysis reaffirming the use of quadruplet therapy with anti-CD38 for newly diagnosed multiple myeloma as the standard of care.
3. CARTITUDE-4: study highlights the benefits of CAR-T therapy in earlier lines of treatment for patients with lenalidomide-refractory disease.
4. Role of IVIG with BCMA Bispecific Antibodies: Discover how IVIG can reduce infection rates and improve overall survival when used alongside BCMA-targeted therapies.
Tune in for an insightful discussion that will enhance your understanding of the latest advancements in multiple myeloma treatment. Don't forget to check out our other episodes on CLL, myeloma, and lymphoma from ASH 2024!
Subscribe to the Oncology Brothers for more updates and expert insights in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
319 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
116 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
289 Listeners
White Coat Investor Podcast
2,431 Listeners
The Curbsiders Internal Medicine Podcast
3,339 Listeners
Core IM | Internal Medicine Podcast
1,149 Listeners
The ONS Podcast
199 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners